# A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

> **NCT01080066** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 215 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT01080066
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2014-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080066, "A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01080066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*